Blockchain Registration Transaction Record

Regentis Biomaterials' GelrinC® Poised to Transform Knee Cartilage Repair

Regentis Biomaterials advances GelrinC, a cell-free hydrogel for knee cartilage repair, targeting a $3B U.S. market. Phase III trial progress and CE Mark approval highlight potential alternative to microfracture.

This news matters because it introduces a potential paradigm shift in knee cartilage repair. GelrinC® could offer a simpler, faster, and more effective alternative to current treatments like microfracture, which often yields mixed results, and complex cell-based therapies that require multiple surgeries. For the 470,000 Americans who suffer knee cartilage damage each year, a one-step, off-the-shelf solution could mean reduced pain, faster recovery, and better long-term outcomes. The product's progress through a pivotal U.S. trial and its CE Mark approval in Europe signal a significant step toward addressing a critical unmet medical need.